Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05145894
Other study ID # ? 4-3/YH-2056/LP05
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 30, 2021
Est. completion date September 30, 2022

Study information

Verified date November 2021
Source Healthy Networks
Contact Helena Binetskaya
Phone +375333130806
Email helena@lungpass.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational study evaluates whether lung sound analysis with LungPass device can be used to differentiate exacerbation and stable state asthma and COPD.


Description:

This is a prospective observational study comprised patients with moderate or severe COPD or asthma exacerbation in primary care settings. Patients will be examined twice - during an exacerbation of the disease and in a stable phase. Patients will undergo routine clinical examination including lung auscultation with conventional stethoscope and LungPass device. Moreover, symptoms and anamnesis data, results of symptoms questionnaires (CAT for COPD and ACQ-5 for asthma), result of diagnostic questionnaire from the LungPass App, spirometry data, serum procalcitonin (for COPD patients), C-reactive protein, white blood cell count and blood eosinophil count, results of sputum cytology examination, Х-ray results (if carried out according to indications) will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date September 30, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria: For COPD patients: - Patients able and willing to sign an informed consent to participate in the study; - Patient is aged 40 years or older with a smoking history of =10 pack years; - Patients with COPD confirmed previously by a detailed medical history and examination; - Patients presenting with moderate or severe exacerbation of chronic obstructive pulmonary disease. - Patient is treated by a monotherapy long-acting muscarinic antagonist (LAMA), or LAMA plus long acting beta2-agonist (LABA), or inhaled corticosteroid (ICS) plus LABA, or LAMA plus LABA plus ICS. For asthma patients: - Patients able and willing to sign an informed consent to participate in the study; - Patient is aged 3 years or older; - Patients with asthma confirmed previously by a detailed medical history and examination; - Patients presenting with moderate or severe exacerbation of asthma; - Patient is treated by a monotherapy ICS or ICS plus LABA or other controllers. Exclusion Criteria: - Age up to 3 years for asthma patients and up to 40 years for COPD patients; - Patient refusal to participate in the study; - Patients with subcutaneous emphysema, with damaged skin on the surface of the chest, with drainage in the pleural space, patients undergoing mechanical ventilation; - Patients with asthma-COPD overlap or presence of other known chronic lung conditions such tuberculosis, cystic fibrosis or clinically significant bronchiectasis; - Mental illness, other known acute diseases or known chronic decompensated diseases, such as a known active malignancy or severe heart failure, other known ongoing infection.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Lung auscultation with LungPass device (electronic auscultation)
Lung auscultation with electronic stethoscope

Locations

Country Name City State
Belarus Minsk Clinical Phthisiopulmonology Center Minsk

Sponsors (3)

Lead Sponsor Collaborator
Healthy Networks Belarusian Medical Academy of Post-Graduate Education, University of Manchester

Country where clinical trial is conducted

Belarus, 

Outcome

Type Measure Description Time frame Safety issue
Other Accuracy of asthma exacerbation detection by LungPass App output ?ccuracy of identifying acute exacerbation of chronic obstructive pulmonary disease and asthma by final LungPass App output which based on abnormal lung sounds detected with LungPass device together with symptoms collected using a questionnaire in the LungPass app*.
* Final LungPass App output is possible patient condition (asthma/asthma exacerbation, COPD/COPD exacerbation, bronchitis, pneumonia, etc)
30.09.2021-30.09.2022
Other Accuracy of COPD exacerbation detection by LungPass App output ?ccuracy of identifying acute exacerbation of chronic obstructive pulmonary disease by final LungPass App output which based on abnormal lung sounds detected with LungPass device together with symptoms collected using a questionnaire in the LungPass app*.
* Final LungPass App output is possible patient condition (asthma/asthma exacerbation, COPD/COPD exacerbation, bronchitis, pneumonia, etc)
30.09.2021-30.09.2022
Primary Accuracy of asthma exacerbation detection by lung sounds Accuracy of identifying acute exacerbation of asthma by abnormal lung sounds detected with LungPass device. 30.09.2021-30.09.2022
Primary Accuracy of COPD exacerbation detection by lung sounds Accuracy of identifying acute exacerbation of chronic obstructive pulmonary disease by abnormal lung sounds detected with LungPass device. 30.09.2021-30.09.2022
Secondary Lung sounds and symptoms correlation in patients with asthma exacerbation Correlation between the presence of pathological pulmonary sounds and the presence of symptoms of asthma exacerbation 30.09.2021-30.09.2022
Secondary Lung sounds and symptoms correlation in patients with COPD exacerbation Correlation between the presence of pathological pulmonary sounds and the presence of symptoms of COPD exacerbation 30.09.2021-30.09.2022
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Completed NCT04102800 - Benralizumab Exacerbation Study Phase 4